On March 28, 2023, AceMab and Jinyu Boworunze Biotechnology (hereinafter "Jinyu Bio") announced a strategic partnership to co-develop therapeutic fully human bispecific antibodies.

Dr. Jianliang Li, CEO of AceMab , stated:

"We are honored to collaborate with Jinyu Bio. Our proprietary AceMouse™ platform and expert discovery team will provide comprehensive support for Jinyu’s fully human antibody development. Furthermore, the Taichu Group’s integrated services—spanning PD/PK/Tox/CMC—will ensure continuity in subsequent stages. Through in-depth discussions with Dr. Zhao, we recognize Jinyu’s commitment to human therapeutics. Together, we will advance the development of effective drugs."

Dr. Mingzhi Zhao, General Manager of Jinyu Bio, commented:

"As a newcomer to biopharmaceuticals, Jinyu Bio leverages its parent company’s resources and Danyang industrial base to advance innovative and biosimilar drug industrialization. We are privileged to partner with AceMab and believe Dr. Li’s team will maximize the value of their proprietary antibody platform. This collaboration will initially focus on bispecific antibodies in autoimmunity, with plans to expand into multiple autoimmune targets."

About AceMab

Established in August 2021 and headquartered in the Lingang Special Area (Shanghai), AceMab evolved from Hunan Huakang Hengjian Biotechnology. As a subsidiary of the Taichu Group, AceMab is a CRO company focused on developing fully human therapeutic monoclonal antibody drugs.

The company leverages its proprietary and independently developed AceMouse™ series platforms (AceMouse™, AceMouseCL™, AceMouseNB™), recognized as one of the world’s leading antibody humanization mouse platforms. This technology enables efficient R&D of therapeutic antibodies, bispecific antibodies, and nanobodies. AceMab offers end-to-end solutions encompassing drug discovery, efficacy/safety evaluation, and CMC services.

About Jinyu Boworunze Biotechnology

Jinyu Boworunze Biotechnology, established in 2020 with a registered capital of ¥175.32 million, is a wholly owned subsidiary of Jinyu Group (SSE: 600201; market cap: ¥21 billion as of 2020). Backed by Jinyu Group’s expertise in animal vaccine R&D and manufacturing, Jinyu Bio focuses on human antibody drugs. Its lead project is a biosimilar of Tocilizumab (MA application submitted in January 2023).

Jinyu Bio’s production base, located in Danyang Economic Development Zone (Jiangsu), is part of a ¥1.5 billion provincial key project. The 88-acre facility spans 56,621.93 sqm and includes:

Two 1000L production lines (annual capacity: 96 kg)

One 5000L production line (annual capacity: 240 kg)

Supporting facilities for formulation, QC/PD labs, and warehousing.

Upon full operation, the project is projected to generate annual revenue of ¥3.486 billion.